About Qrumpharma
Qrumpharma is a company based in Doylestown (United States) founded in 2014 was acquired by MannKind Corp in December 2020. Qrumpharma operates in a competitive market with competitors including Actelion, Kriya Therapeutics, Sana Biotechnology, Semma Therapeutics and Cellino, among others.
- Headquarter Doylestown, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
MannKind Corp
(Dec 07, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Qrumpharma
Detailed funding history for Qrumpharma
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Qrumpharma
Qrumpharma has secured backing from 1 investor. Prominent investors backing the company include MannKind Corp.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of small-molecule drugs
|
Locked | Locked | Locked |
Investor details for Qrumpharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Qrumpharma
Investment portfolio details for Qrumpharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Qrumpharma
Detailed financials for Qrumpharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Qrumpharma Comparisons
Peer comparison for Qrumpharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Qrumpharma
Qrumpharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Actelion, Kriya Therapeutics, Sana Biotechnology, Semma Therapeutics and Cellino, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Innovative treatments for orphan diseases are discovered, developed, and commercialized.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
Detailed competitors of Qrumpharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Qrumpharma
Complete news archive for Qrumpharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Qrumpharma
Qrumpharma was founded in 2014.
Qrumpharma is headquartered in Doylestown, United States. It is registered at Doylestown, Pennsylvania, United States.
Qrumpharma was founded in 2014 and is based in Doylestown, United States. Operations are centered in the pharmaceutical sector, where therapeutics for diabetes and respiratory disorders are developed. Products such as Afrezza and Pediatric Afrezza Inhalation Powder are provided for diabetes mellitus treatment, while Thyquidity levothyroxine solution is offered for hypothyroidism. Additional items include Tyvaso DPI for pulmonary hypertension and Cannabidiol Technosphere for panic attacks.
Qrumpharma's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
Qrumpharma has 1 investor. Key investors include MannKind Corp.